Pancreatic cancer: FDA approves new drug
The first-of-its-kind RAS inhibitor cut the risk of death in trials and raised median overall survival from 6.7 months to 13.2 months, researchers said.
5 Articles
5 Articles
GU Professor Leads SOM Seminar on Newly Approved Pancreatic Cancer Drugs, Innovative Treatment
A Georgetown University School of Medicine professor argued that a recently approved drug to treat pancreatic cancer will transform the disease’s future treatment. The U.S. Food and Drug Administration (FDA) approved daraxonrasib, a first-of-its-kind drug that significantly reduced the risk of death in metastatic pancreatic cancer patients in clinical trials, the FDA announced Aug. 26....
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
The US FDA approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. [US FDA] Press Release
Oncological research has reached a decisive stage in the treatment of dark prognosis cancer pathologies. The emergence of molecular inhibitors capable of blocking cell mutations finally offers prospects for prolonged survival to patients. By directly targeting genetic anomalies responsible for the proliferation of tumours, these therapies revolutionize traditional clinical protocols. Understanding the mechanisms of these medical innovations allo…
Coverage Details
Bias Distribution
- 67% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
